| 注册
首页|期刊导航|癌症(英文版)|The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma

Zhi-Tao Ying Chen Zhang Jun Zhu Yu-Qin Song Wen Zheng Xiao-Pei Wang Yan Xie Mei-Feng Tu Ning-Jing Lin Ling-Yan Ping Wei-Ping Liu Li-Juan Deng

癌症(英文版)2012,Vol.31Issue(7):348-353,6.
癌症(英文版)2012,Vol.31Issue(7):348-353,6.DOI:10.5732/cjc.011.10469

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma

Zhi-Tao Ying 1Chen Zhang 1Jun Zhu 1Yu-Qin Song 1Wen Zheng 1Xiao-Pei Wang 1Yan Xie 1Mei-Feng Tu 1Ning-Jing Lin 1Ling-Yan Ping 1Wei-Ping Liu 1Li-Juan Deng1

作者信息

  • 1. Author'Affiliation: Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Lymphoma Department,Peking University Canc er Hospital & Institute,Beijing 100142,P. R. China
  • 折叠

摘要

Abstract

Mantle cell lymphoma (MCL),a special type of non-Hodgkin's lymphoma,is incurable through conventional treatment.This study aimed to analyze the clinical features,therapeutic responses,and prognosis of patients with MCL.Clinical data of 30 patients with MCL treated in our hospital between April 2006 and July 2011 were analyzed.Eighteen patients were treated with CHOP plus rituximab (R-CHOP)regimen,12 underwent conventional chemotherapy.The median age of the 30 patients was 58 years,23were men,all patients had Cyclin D1 overexpression,29 (96.7%) had advanced disease,11 (36.7%) had bone marrow involvement,9 (30.0%) had gastrointestinal involvement,and 15 (50.0%) had splenomegaly.The complete response (CR) rate and overall response rate (ORR) were significantly higher in patients undergoing R-CHOP immunochemotherapy than in those undergoing conventional chemotherapy (38.9%vs.16.7%,P =0.187; 72.2% vs.41.4%,P =0.098).The difference of 2-year overall survival rate between the two groups was not significant (P =0.807) due to the short follow-up time.The 2-year progression-free survival (PFS) rate was higher in R-CHOP group than in conventional chemotherapy group (53% vs.25%,P =0.083),and was higher in patients with a lower mantle cell lymphoma international prognostic index (MIPI) (51% for MIPI 0-3,33% for MIPI 4-5,and 0% for MIPI 6-11,P =0.059).Most patients with MCL were elderly; in an advanced stage; showed a male predominance; and usually had bone marrow involvement,gastrointestinal involvement,or splenomegaly.R-CHOP regimen could improve the CR rate and ORR of MCL patients.MIPI can be a new prognostic index for predicting the prognosis of advanced MCL.

关键词

Mantle cell lymphoma/clinical features/therapeutic efficacy/prognosis

Key words

Mantle cell lymphoma/clinical features/therapeutic efficacy/prognosis

引用本文复制引用

Zhi-Tao Ying,Chen Zhang,Jun Zhu,Yu-Qin Song,Wen Zheng,Xiao-Pei Wang,Yan Xie,Mei-Feng Tu,Ning-Jing Lin,Ling-Yan Ping,Wei-Ping Liu,Li-Juan Deng..The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma[J].癌症(英文版),2012,31(7):348-353,6.

癌症(英文版)

OACSCDCSTPCDSCI

1000-467X

访问量1
|
下载量0
段落导航相关论文